A clinical trial to study the efficacy of two drugs ,secukinumab and adalimumab in the treatment of hidradenitis suppurativa

Efficacy Of Secukinumab Vs Adalimumab in the treatment Of Hidradenitis Suppurativa: A Randomized Controlled Trial - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093223

Enrollment

Registered

2025-08-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L732- Hidradenitis suppurativa

Interventions

Intervention1: Secukinumab: Injection Secukinumab 300 mg sc onve every 4 weekly Control Intervention1: Adalimumab: Injection Adalimumab 120 mg sc every 4 weekly

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases Of Hidradenitis Suppurativa with poor response to conventional therapy for more than 12 months

Exclusion criteria

Exclusion criteria: Pregnant ladies, autoimmune disorders, immunocompromised patients

Design outcomes

Primary

Measure	Time frame
Clinical response to treatment by assessing modified sartorius scoreTimepoint: 4 weekly	—

Secondary

Measure	Time frame
Clinical response to treatment by assessing hurley staging & patient satisfaction levelTimepoint: 4 weekly	—

Countries

India

Contacts

Public ContactDebatraya paul

Military Hospital Jaipur

drdebatrayapaul@gmail.com9432879780

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026